NF-κB activation is required for adaptive cardiac hypertrophy

Cardiovascular Research

Volumn 84, Issue 3, 2009, Pages 416-424

  Zelarayan, Laura ^a,b   Renger, Anke ^a,b   Noack, Claudia ^a,b   Zafiriou, Maria Patapia ^a,b   Gehrke, Christina ^a,b   Van Der Nagel, Roel ^c   Dietz, Rainer ^a,b   De Windt, Leon ^c   Bergmann, Martin W ^a,b  

^a Experimental and Clinical Research Center   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiotensin; Apoptosis; Fibrosis; Hypertension; Hypertrophy; NF B; Remodelling; Signal transduction

Indexed keywords

ACTIN; ALPHA SKACTIN; ANDROSTANOLONE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CRE RECOMBINASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; MYOSIN HEAVY CHAIN ALPHA; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; I KAPPA B; MYOSIN HEAVY CHAIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; LOXP SITE; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STRESS; TRANSGENIC MOUSE; ANIMAL; APOPTOSIS; C57BL MOUSE; CARDIOMEGALY; DISEASE MODEL; DRUG ANTAGONISM; FIBROSIS; GENETICS; HEART MUSCLE; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; I-KAPPA B PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; MYOCARDIUM; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; NF-KAPPA B; RECEPTOR, ANGIOTENSIN, TYPE 1; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 70849134670     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp237     Document Type: Article

References (14)

1. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov 2007;6:617-635.
2. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002;105:85-92.
3. Skavdahl M, Steenbergen C, Clark J, Myers P, Demianenko T, Mao L et al. Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol 2005;288:H469-H476.
4. Gerdts E, Okin PM, de Simone G, Cramariuc D, Wachtell K, Boman K et al. Gender differences in left ventricular structure and function during anti-hypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008;51:1109-1114.
5. Freshour JR, Chase SE, Vikstrom KL. Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice. Am J Physiol Heart Circ Physiol 2002;283:H1997-H2003.
6. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P et al. Requirement of nuclear factor-kappaB in angiotensin II-and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005; 111:2319-2325.
7. Schmidt-Ullrich R, Aebischer T, Hulsken J, Birchmeier W, Klemm U, Scheidereit C. Requirement of NF-kappaB/Rel for the development of hair follicles and other epidermal appendices. Development (Cambridge, England) 2001;128:3843-3853.
8. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpres-sion of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000;97:931-936.
9. van Empel VP, Bertrand AT, van Oort RJ, van der Nagel R, Engelen M, van Rijen HV et al. EUK-8, a superoxide dismutase and catalase mimetic, reduces cardiac oxidative stress and ameliorates pressure overload-induced heart failure in the harlequin mouse mutant. J Am Coll Cardiol 2006;48:824-832.
10. Baurand A, Zelarayan L, Betney R, Gehrke C, Dunger S, Noack C et al. Beta-catenin downregulation is required for adaptive cardiac remodeling. Circ Res 2007;100:1353-1362.
11. Krappmann D, Wulczyn FG, Scheidereit C. Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo. EMBO J 1996;15:6716-6726.
12. Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004;110: 718-723.
13. Kang PM, Yue P, Liu Z, Tarnavski O, Bodyak N, Izumo S. Alterations in apoptosis regulatory factors during hypertrophy and heart failure. Am J Physiol Heart Circ Physiol 2004;287:H72-H80.
14. Baltatu O, Cayla C, Iliescu R, Andreev D, Bader M. Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats. Hypertension 2003;41:830-833.